Satellos Bioscience (TSX:MSCL) Change In Receivables : C$-0.83 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience Change In Receivables?

Satellos Bioscience's change in receivables for the quarter that ended in Mar. 2024 was C$-0.31 Mil. It means Satellos Bioscience's Accounts Receivable increased by C$0.31 Mil from Dec. 2023 to Mar. 2024 .

Satellos Bioscience's change in receivables for the fiscal year that ended in Dec. 2023 was C$-0.32 Mil. It means Satellos Bioscience's Accounts Receivable increased by C$0.32 Mil from Dec. 2022 to Dec. 2023 .

Satellos Bioscience's Accounts Receivable for the quarter that ended in Mar. 2024 was C$0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Satellos Bioscience's liquidation value for the three months ended in Mar. 2024 was C$29.42 Mil.

Satellos Bioscience Change In Receivables Historical Data

The historical data trend for Satellos Bioscience's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience Change In Receivables Chart

Satellos Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Receivables

0.26

-0.07

0.27

-0.32

Satellos Bioscience Quarterly Data
	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial										0.20	-0.29	-	-0.23	-0.31

Satellos Bioscience Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.83 Mil.

Satellos Bioscience (TSX:MSCL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Satellos Bioscience's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Satellos Bioscience's accounts receivable are only considered to be worth 75% of book value:

Satellos Bioscience's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	33.171	-	3.754	+	0.75 * 0	+	0.5 * 0
=	29.42

Satellos Bioscience Change In Receivables Related Terms

Thank you for viewing the detailed overview of Satellos Bioscience's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Satellos Bioscience (TSX:MSCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

MSCLF:USA 0IT:Germany

Address

65 Front Street East, Suite 201, Toronto, ON, CAN, M5E 1B5

Website

https://www.satellos.com

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience (TSX:MSCL) Headlines

No Headlines